Overview
Increasing bacterial resistance coupled with decreasing research on new antibacterial drugs is creating a crisis that could disproportionately impact our most vulnerable populations, including children and the seriously ill.
CTTI has created approaches for streamlining antibacterial drug development that will help you design clinical trials that better assess the efficacy and safety of new antibacterial drugs and inform clinical trial planning, recruitment, enrollment, and feasibility. Use CTTI’s recommendations and resources to help combat this complex public health concern.
Projects
Learn about CTTI’s prospective, multi-center, observational study of the risk factors for HABP/VABP.
Design pediatric antibacterial trials that ensure adequate enrollment, decrease the burden on sites and families, and increase engagement with healthcare providers.
ABDD STREAMLINING HABP/VABP TRIALS
Streamline protocol elements and data collection in HABP/VABP trials to increase enrollment, reduce trial complexity, and optimize operational efficiency.
Read about CTTI’s research findings on patient and physician perspectives and considerations as it relates to using antibacterial drugs developed through streamlined development processes.
News
- New CTTI Paper Outlines Risk Factors to Aid in HABP/VABP Pediatric Trial EnrollmentA CTTI paper recently published in the Pediatric Infectious Disease Journal sheds light on risk factors that make children more likely to contract hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). These risk factors are ...